ProCE Banner Activity

ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL

Slideset Download
Conference Coverage
In this head-to-head, randomized phase III trial, acalabrutinib proved to be noninferior to ibrutinib for PFS and demonstrated a more favorable safety profile, particularly regarding cardiovascular events.

Released: June 09, 2021

Expiration: June 08, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme